Fance
- Known as:
- Fance
- Catalog number:
- 048826A
- Product Quantity:
- 250ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- Fance
Related genes to: Fance
- Gene:
- FANCE NIH gene
- Name:
- FA complementation group E
- Previous symbol:
- FACE
- Synonyms:
- FAE
- Chromosome:
- 6p21.31
- Locus Type:
- gene with protein product
- Date approved:
- 1996-04-09
- Date modifiied:
- 2019-04-23
Related products to: Fance
Related articles to: Fance
- In the North Thames Mainstreaming of Breast Cancer Genetic Testing (NT-MBGT) programme, we piloted testing for breast cancer susceptibility genes (BCSGs) in unselected breast cancer (BC) patients, deploying a clinician-light 'BRCA-DIRECT' mainstreaming pathway; this included home saliva-testing and consent with postal return, written and digital materials, with full access to a Genetic Counsellor Telephone helpline. Across 14 National Health Service (NHS) breast oncology units, we successfully tested 3515 newly-diagnosed BC patients with high levels of patient and breast healthcare professional (HCP) satisfaction and genetics HCPs reporting decreases in service referrals. The pick-up rate of gPVs was 4.7% (166 germline Pathogenic Variants (gPVs) across seven BCSGs). Examining application of current NHS eligibility criteria to the unselected cohort, testing would have been offered to 20.6% of patients with identification of 49.2% of gPVs in high penetrance (HP)-BCSGs (BRCA1/BRCA2/PALB2) and 18.2% of gPVs in intermediate penetrance-BCSGs (CHEK2/ATM/RAD51C/RAD51D). Designing 'Ultra-simple' eligibility criteria suitable for mainstreaming, detection (sensitivity) could be improved to 81.1% and 70.4% respectively, whilst increasing testing to 49.7% of BC cases. Evidence from the NT-MBGT programme demonstrates that expanding BCSG-testing via a clinician-light pathway is acceptable and feasible, without increasing the burden on limited breast and genetics workforce, and has high satisfaction. - Source: PubMed
Publication date: 2026/07/09
Torr BethanyMansour LeaFierheller Caitlin THamill MonicaNolan JoshuaBell NicolaChoi SubinAllen SophieMuralidharan SudeekshnaMacMahon SuzanneClinch YasminValganon-Petrizan MikelHarder HelenaGarrett AliceEvans D GarethGeorge AngelaJenkins ValerieFallowfield LesleyLegood RosaKemp ZoeManchanda RanjitTurnbull Clare - Male breast cancer (MBC) is rare, and its genetic basis remains poorly characterized. Over the past few decades, genetic screening strategies have evolved from analyses focusing solely on the BRCA1/2 genes to extensive multigene panels. Longitudinal data describing this transition in men remain scarce. - Source: PubMed
Publication date: 2026/07/06
Taris NicolasAmand Nile Duflos De SaintHild CaroleMathelin CaroleChrétien Manon - Homologous recombination (HR) deficiency (HRD) from germline BRCA1/2 mutations (gBRCAm) sensitizes high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC) to PARP inhibitors (PARPi), as may promoter methylation of BRCA1 (meBRCA1) or RAD51C (meRAD51C) or mutation of non-BRCA HR genes. This trial evaluated olaparib in platinum-sensitive, relapsed HGSOC (PSROC) and metastatic TNBC (mTNBC) with non-gBRCA HRD. - Source: PubMed
Publication date: 2026/07/08
Sjoquist Katrin MDobrovic AlexanderRobledo Kristy PNesic KsenijaBaron-Hay SallyAnanda SumitraMcCarthy NicoleGoh JeffreySteer ChristopherMurray NickYip SoniaMileshkin Linda RFink J LynnChang GarryBailey LisaLee YvonneZebic Danka SKariyawasam U G Imalki UShield-Artin KristyJarratt AndrewBedő JustinPapenfuss Anthony TKondrashova OlgaWakefield Matthew JVandenberg Cassandra JStockler Martin RScott Clare LWaring Paul M - Patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination deficiency (HRD) benefit from poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) or platinum-based chemotherapy (PlCh). Pathogenic variants in homologous recombination repair genes are used as a proxy for the phenotype. Genomic Instability Score (GIS) is a metric for the effect of HRD. This study used shallow whole-genome sequencing (sWGS), a cost-effective alternative to full-depth WGS, to calculate GIS and evaluate its predictive value for PARPi or PlCh response. - Source: PubMed
Publication date: 2026/07/08
Slootbeek Peter H JQuint Yarah MKokke Julian J RPamidimarri Naga SamhitaLuna-Velez Maria VictoriaLigtenberg Marjolijn J Lde Voer Richarda MMehra Niven - Invasive lobular carcinoma (ILC) represents the second most common histologic subtype of breast cancer (BC), yet its genomic landscape and clinical implications remain less well defined compared with invasive ductal carcinoma. Understanding genetic predisposition in ILC may improve risk assessment and guide tailored clinical management. - Source: PubMed
Publication date: 2026/07/01
Corso GiovanniMarino ElenaFava FrancescaNatali FabrizioPeterlongo PaoloDal Molin MatteoFeroce IreneZanzottera CristinaMassari GiuliaDi Silvestre SusannaMoscatiello MicolFranceschini AndreaBagnardi VincenzoCurigliano GiuseppeBonanni BernardoVeronesi PaoloBertolini Francesco